SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy

BACKGROUND: SARS-CoV-2 enters cells by binding of its spike protein to angiotensin-converting enzyme 2 (ACE2). Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have been reported to increase ACE2 expression in animal models, and worse outcomes are reported...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:EBioMedicine
Asıl Yazarlar: Chung, Mina K., Karnik, Sadashiva, Saef, Joshua, Bergmann, Cornelia, Barnard, John, Lederman, Michael M., Tilton, John, Cheng, Feixiong, Harding, Clifford V., Young, James B., Mehta, Neil, Cameron, Scott J., McCrae, Keith R., Schmaier, Alvin H., Smith, Jonathan D., Kalra, Ankur, Gebreselassie, Surafel K., Thomas, George, Hawkins, Edward S., Svensson, Lars G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2020
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415847/
https://ncbi.nlm.nih.gov/pubmed/32771682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102907
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller